Table 1

FN rates in the main trials of association between chemotherapy and immunotherapy

TrialCancer typeDrugsFN: chemotherapy+immunotherapy armFN: chemotherapy armG-CSF or GM-CSF use
KEYNOTE-407NSCLC squamousPembrolizumab+carboplatin+(nab)-paclitaxel5.4%3.6%Permitted as for guidelines
KEYNOTE-189NSCLC non-squamousPembrolizumab+cis-‚ÄČor carboplatin+pemetrexed5.7%2.0%Permitted as for guidelines
IMpower133SCLCAtezolizumab+carboplatin+etoposide2.5%4.4%NA
KEYNOTE-048HNSCCPembrolizumab+cis-‚ÄČor carboplatin+5-fluorouracil6.2%5.2%Permitted as for guidelines
IMpassion130Breast cancerAtezolizumab+nab-paclitaxel1.9%2.2%NA
  • FN, febrile neutropenia; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; HNSCC, head and neck squamous cell carcinoma; NA, not available; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.